Stay updated on Lenvatinib and Pembrolizumab in HCC Clinical Trial
Sign up to get notified when there's something new on the Lenvatinib and Pembrolizumab in HCC Clinical Trial page.

Latest updates to the Lenvatinib and Pembrolizumab in HCC Clinical Trial page
- Check5 days agoChange DetectedThe page’s revision tag was updated from v3.6.0 to v3.6.2. This reflects a minor update to the page content rather than substantive changes to the study details.SummaryDifference0.0%

- Check12 days agoNo Change Detected
- Check19 days agoChange DetectedThe page now indicates enrollment is closed for this study, and new sections titled How to Read a Study Record, Common Questions, and How to Join a Study have been added; the Intervention/Treatment header formatting was adjusted and the revision version updated to v3.6.0.SummaryDifference0.2%

- Check27 days agoChange DetectedRevision updated from v3.5.4 to v3.5.5, indicating a newer version of the document label on the page. It reflects an update to the page's versioning rather than substantive content changes.SummaryDifference0.0%

- Check48 days agoChange DetectedThe revision label has been updated from Revision: v3.5.3 to Revision: v3.5.4. This reflects a newer revision of the document in the revision history.SummaryDifference0.0%

- Check55 days agoChange DetectedTaoyuan District, Taiwan, 333 was removed and Taoyuan, Taiwan, 333 was added in the Locations section, reflecting a corrected city designation for the recruitment site.SummaryDifference0.0%

- Check62 days agoChange DetectedThe page's revision label has been updated from v3.5.2 to v3.5.3. This reflects a minor update to the page's metadata or documentation.SummaryDifference0.0%

Stay in the know with updates to Lenvatinib and Pembrolizumab in HCC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Lenvatinib and Pembrolizumab in HCC Clinical Trial page.